ERBB2 and gastric cancer: GC is a clinically heterogeneous disease, and besides surgery and chemotherapy, only traztuzumab (anti-HER2) and ramucirumab (anti-VEGFR2) are approved clinically with other molecularly targeted agents proving unsuccessful to date20.